On Thursday, 20th June, 2024, at the Global Forum for Vaccine Sovereignty and Innovation in Paris, France, President Akufo-Addo emphasized the critical need for collaborative efforts towards advancing vaccine sovereignty and fostering innovation.
Highlighting the approval of the African Vaccine Manufacturing Accelerator (AVMA) at the recent Gavi Board meeting in Accra, the initiative, spearheaded by Gavi and the Africa Centre for Disease Control and Prevention, aligns with the African Union’s goal to manufacture at least 60% of the continent’s vaccine doses by 2040.
In Ghana, aside integrating COVID-19 vaccination into our routine programs, maintaining robust immunization efforts and increasing efforts to achieve full self-vaccine manufacturing financing by January 2030, Ghana plans to expand its vaccination schedule to include Malaria, Human Papilloma Virus (HPV), Hepatitis B, and additional doses of Inactivated Polio Vaccine (IPV). The geographical coverage of the malaria vaccine will increase significantly, from 136 to 261 districts by 2030.
In May 2023, President Akufo-Addo commissioned the Ghana National Vaccine Institute to coordinate vaccine research, development, and manufacturing.
The Institute is working to establish domestic vaccine manufacturing plants and market development, supporting human resource capacity-building and strengthening research and development.
It collaborates with regulatory bodies to ensure adherence to global standards and facilitate technology transfer.
Source:Mybrytfmoline.com/Kwabena Nyarko Abronoma
